Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design | Zendy

Tadej Battelino | Zendy; Zsolt Bosnyák | Zendy; Thomas Danne | Zendy; B.N. Mukherjee | Zendy; Steve Edelman | Zendy; Valérie Pilorget | Zendy; Pratik Choudhary | Zendy; Éric Renard | Zendy; Richard M. Bergenstal | Zendy

Open Access

Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

Author(s) -

Tadej Battelino,

Zsolt Bosnyák,

Thomas Danne,

B.N. Mukherjee,

Steve Edelman,

Valérie Pilorget,

Pratik Choudhary,

Éric Renard,

Richard M. Bergenstal

Publication year - 2020

Publication title -

diabetes therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.907

H-Index - 33

ISSN - 1869-6961

DOI - 10.1007/s13300-020-00820-2

Subject(s) - insulin degludec , insulin glargine , medicine , continuous glucose monitoring , basal insulin , type 2 diabetes , diabetes mellitus , basal (medicine) , type 1 diabetes , endocrinology

In the original publication, the timing of baseline CGM assessment was incorrectly stated in the text in two instances; it is correct in Fig. 1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research